Bresat Cancer Update
Oncology Leader CommentarySpecial FeaturesPrevious Issues

Home: Oncology Leader Commentary: J. Michael Dixon, MD

Click on the topic below for comments by Dr J. Michael Dixon to comment on. You will also find links to related articles and clinical trials.

Breast cysts as a cancer risk factor
Biochemistry of breast cysts
Intratumoral estrogen levels in breast cancer
Neoadjuvant endocrine therapy
Response rates with neoadjuvant endocrine therapy
Time to response with neoadjuvant endocrine therapy
Randomized trials of neoadjuvant Arimidex
Response criteria with neoadjuvant therapy
Biologic effect of endocrine agents
Combining endocrine agents
Quality of life with neoadjuvant endocrine therapy
Neoadjuvant endocrine therapy of locally advanced breast cancer
Neoadjuvant therapy of inflammatory breast cancer
Neoadjuvant therapy of elderly patients
Timing of surgery after neoadjuvant therapy
Neoadjuvant therapy with aromatase inhibitors

Intratumoral estrogen levels in breast cancer

Play Audio Below:

The interesting issue for me is the fact that postmenopausal women have levels of estrogen in their cancers equivalent to those of premenopausal women despite the fact that premenopausal women have much higher levels of circulating estrogen. So the issue is where does that estrogen come from? And what’s interesting or surprising is that in many tumors, the tumor itself produces either part or all of that estrogen. And if you look at the relationship between the amount of estrogen a tumor produces and estrogen receptor positivity, estrogen receptor-positive tumors are more likely to produce high levels of estrogen, so it’s like the tumors doing it for itself. And this data is relevant because a large percentage of the estrogen in some cancers and in some tumors, all the estrogen in the cancer comes from in situ synthesis – that’s synthesis by the tumor itself.

What’s happening in these tumors with estrogen receptor – they obviously need the estrogen to keep alive and to grow. And the tumors themselves developed this ability to be self-maintaining, to make their own estrogen by taking up circulating androgens and converting it through the aromatase enzyme to estrogen. So it’s pretty clever by the tumors, really.

Relevant Articles:

Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues.
Chetrite GS. Cortes-Prieto J. Philippe JC. Wright F. Pasqualini JR. Journal of Steroid Biochemistry & Molecular Biology. 72(1-2):23-7, 2000.

Youth and hormone receptors in breast cancer: good or bad news first?
Stockler, M. and Beith, J. Lancet. 355(9218):1839-1840, 2000 May 27. No abstract

Top of Page

Home · Contact us
Terms of use and general disclaimer